TrialBMC infectious diseases2020

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections.

Weiqiang Gan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.